Role of fibroblast growth factor 23 in health and in chronic kidney disease
暂无分享,去创建一个
[1] S. Fukumoto,et al. Intravenous Calcitriol Therapy Increases Serum Concentrations of Fibroblast Growth Factor-23 in Dialysis Patients with Secondary Hyperparathyroidism , 2005, Nephron Clinical Practice.
[2] B. Deyoung,et al. Elevated fibroblast growth factor‐23 in hypophosphatemic linear nevus sebaceous syndrome , 2005, American journal of medical genetics. Part A.
[3] A. Delezoide,et al. Expression of fibroblast growth factors 18 and 23 during human embryonic and fetal development. , 2005, Gene expression patterns : GEP.
[4] I. Narita,et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. , 2005, Kidney international.
[5] T. Shigematsu,et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. , 2005, Kidney international.
[6] R. Rizzoli,et al. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. , 2005, The Journal of clinical endocrinology and metabolism.
[7] K. White,et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. , 2005, American journal of human genetics.
[8] P. Orlik,et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.
[9] S. Kato,et al. Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo* , 2005, Journal of Biological Chemistry.
[10] K. Miyamoto,et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. , 2005, American journal of physiology. Endocrinology and metabolism.
[11] M. Razzaque,et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[12] R. Mason,et al. Bone as a source of FGF23: regulation by phosphate? , 2004, Bone.
[13] D. Miao,et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. , 2004, Endocrinology.
[14] M. Econs,et al. FGF-23 is elevated by chronic hyperphosphatemia. , 2004, The Journal of clinical endocrinology and metabolism.
[15] N. Goto,et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] Kozo Nakamura,et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. , 2004, The Journal of clinical endocrinology and metabolism.
[17] T. Shigematsu,et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] T. Strom,et al. FGF23 is processed by proprotein convertases but not by PHEX. , 2004, Bone.
[19] T. Shigematsu,et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. , 2004, European journal of endocrinology.
[20] C. Ohlsson,et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. , 2004, Endocrinology.
[21] M. Inaba,et al. FGF-23 in patients with end-stage renal disease on hemodialysis. , 2004, Kidney international.
[22] S. Kato,et al. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. , 2004, American journal of physiology. Renal physiology.
[23] Y. Takeuchi,et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.
[24] T. Yoneya,et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. , 2004, Biochemical and biophysical research communications.
[25] Y. Takeuchi,et al. FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] H. Jüppner,et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. , 2003, Kidney international.
[27] H. Murer,et al. Regulation of Na/Pi transporter in the proximal tubule. , 2003, Annual review of physiology.
[28] L. Quarles,et al. Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX* , 2003, Journal of Biological Chemistry.
[29] K. White,et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.
[30] S. Fukumoto,et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.
[31] K. Miyamoto,et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter , 2003, Pflügers Archiv.
[32] L. Quarles,et al. Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] D. Miao,et al. The Autosomal Dominant Hypophosphatemic Rickets R176Q Mutation in Fibroblast Growth Factor 23 Resists Proteolytic Cleavage and Enhances in Vivo Biological Potency* , 2003, The Journal of Biological Chemistry.
[34] K. Miyamoto,et al. Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.
[35] Y. Takeuchi,et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.
[36] Nobuyuki Itoh,et al. Fibroblast Growth Factor (FGF)-23 Inhibits Renal Phosphate Reabsorption by Activation of the Mitogen-activated Protein Kinase Pathway* , 2002, The Journal of Biological Chemistry.
[37] T. Yoneya,et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. , 2002, Endocrinology.
[38] R. Kumar,et al. Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] T. Strom,et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. , 2001, Kidney international.
[40] L. Quarles,et al. Analysis of recombinant Phex: an endopeptidase in search of a substrate. , 2001, American journal of physiology. Endocrinology and metabolism.
[41] J. Bertram,et al. Fibroblast growth factor receptors and their ligands in the adult rat kidney. , 2001, Kidney international.
[42] R. Kumar,et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. , 2001, Biochemical and biophysical research communications.
[43] S. Takeda,et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[44] T. Meitinger,et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.
[45] N. Itoh,et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. , 2000, Biochemical and biophysical research communications.
[46] A. Poustka,et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets , 1995, Nature Genetics.
[47] Y. Takeuchi,et al. Targeted ablation of Fgf 23 demonstrates an essential physiological role of FGF 23 in phosphate and vitamin D metabolism , 2004 .
[48] R. Kumar,et al. The phosphatonin pathway: new insights in phosphate homeostasis. , 2004, Kidney international.
[49] K. White,et al. Renal phosphate wasting disorders: clinical features and pathogenesis. , 2004, Seminars in nephrology.
[50] L. Quarles,et al. REGULATION OF FGF 23 EXPRESSION BUT NOT DEGRADATION BY PHEX , 2003 .